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Abstract
Background: Recent studies have shown that intermittent preventive malaria treatment (IPT) in infants
in areas of stable malaria transmission reduces malaria and severe anaemia incidence. However in most
areas malaria morbidity and mortality remain high in older children.
Methods: To evaluate the effect of seasonal IPT with sulphadoxine pyrimethamine (SP) on incidence of
malaria disease in area of seasonal transmission, 262 children 6 months-10 years in Kambila, Mali were
randomized to receive either IPT with SP twice at eight weeks interval or no IPT during the transmission
season of 2002 and were followed up for 12 months. Subjects were also followed during the subsequent
transmission season in 2003 to assess possible rebound effect. Clinical malaria cases were treated with SP
and followed to assess the in vivo response during both periods.
Results: The incidence rate of malaria disease per 1,000 person-months during the first 12 months was
3.2 episodes in the treatment group vs. 5.8 episodes in the control group with age-adjusted Protective
Efficacy (PE) of 42.5%; [95% CI 28.6%–53.8%]. When the first 16 weeks of follow up is considered age-
adjusted PE was 67.5% [95% CI 55.3% – 76.6%]. During the subsequent transmission season, the incidence
of clinical malaria per 1000 persons-days was similar between the two groups (23.0 vs 21.5 episodes, age-
adjusted IRR = 1.07 [95% CI, 0.90–1.27]). No significant difference was detected in in vivo response
between the groups during both periods.
Conclusion: Two malaria intermittent treatments targeting the peak transmission season reduced the
annual incidence rate of clinical malaria by 42.5% in an area with intense seasonal transmission. This simple
strategy is likely to be one of the most effectives in reducing malaria burden in such areas.
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Background
Malaria is one of the most common infectious diseases in
the world. It is estimated that malaria causes between 300
and 500 million clinical cases and 700,000 to 1.6 million
deaths each year with 94% of deaths occurring in sub-
Saharan Africa [1,2].
In Mali, malaria is the leading cause of mortality and mor-
bidity in the general population [3]. Like in many other
Sahelian west African countries, malaria transmission is
highly seasonal occurring during the rainy season, which
varies from three to six months. It has been shown that
more than 80% of malaria cases occurred during five
months of the transmission season in the north savanna
area of Mali. In such conditions, a suitable control strategy
implemented during this period may have the most
impact on the reduction of disease burden.
In the absence of vaccines, early case management and the
use of insecticide-impregnated material are the best strat-
egies to control malaria. However, their implementation
has been slow and difficult to achieve due to the overarch-
ing poverty and illiteracy of the population as well as the
insufficiency and inaccessibility of health services in most
endemic areas. Home- and self-treatment have been pro-
posed as alternatives to the insufficiency and inaccessibil-
ity of the health services, but these strategies have also
several disadvantages, including misdiagnoses, lack of
compliance with drug regimens, use of inappropriate
medicine, which could contribute to development of drug
resistance and the non-recognition of the severity of
symptoms [4,5]. Consequently in sub-Saharan Africa, the
morbidity and mortality of malaria are increasing [6].
There is an urgent need for an easy and simple malaria
control strategy.
Recent, randomized controlled trials conducted in areas
of perennial malaria transmission have shown that inter-
mittent preventive treatment (IPT) given at the time of
childhood vaccinations reduced the incidence of the first
episode of malaria and severe anaemia by more than 50%
during the first year of life, without there being any
rebound in the subsequent year [7,8]. However, in coun-
tries such as Mali, where malaria is highly seasonal and
prevalent in older children, IPT in infants (IPTi) may not
be the optimum way in which to use antimalarial drugs to
prevent malaria. An alternative approach is to give inter-
mittent preventive treatment to children at risk only dur-
ing the rainy season [9]. The primary aim of this study was
to evaluate the impact of two seasonal IPT (sIPT) with sul-
phadoxine-pyrimethamine (SP) given at eight weeks
interval on the incidence of malaria disease in children of
six months to 10 years of age in an area of seasonal trans-
mission, in Kambila, Mali. Secondary aims were to assess
the impact of this strategy on the in vivo response of Plas-
modium falciparum to SP and the potential rebound effect
of this strategy on the subsequent transmission season
after its cessation.
Study design and methods
Study site
The study was conducted in Kambila, a rural village of
about 1,500 inhabitants located about 25 km from
Bamako, the capital city of Mali. Plasmodium falciparum is
hyperendemic with parasitaemia prevalence rates ranging
from 40–50% in the dry season (November – May) and
70–85% in the rainy season (June – October). The bed net
coverage in the area at the time of the survey was less than
5%. The village was chosen to represent an area with four
to five months of seasonal malaria transmission. SP was at
the time, the second-line antimalarial drug in Mali, and
was recommended for chloroquine failures. In 1995, a
previous study found SP efficacy to be greater than 99% in
the neighbouring area [10].
Study participants and design
The study was an open randomized controlled clinical
trial. After a census of the village population, subjects in
the target age group were screened for inclusion and exclu-
sion criteria. Subjects who met inclusion and exclusion
criteria were randomized either to receive two intermit-
tent preventive treatments with standard recommended
treatment doses of SP or no intermittent preventive treat-
ment. Randomization codes were computer generated
using simple randomization technique and treatment
allocations were provided within sealed opaque enve-
lopes. The first treatment was given at the beginning of the
transmission season in July 2002 and the second treat-
ment eight weeks later in August 2002. Inclusion criteria
for the study included: 1) parental or other legal guardian
consent; 2) age six months to 10 years; 3) having no
chronic illness or symptomatic malaria; 4) agreeing to
seek initial medical care for all medical illness in the study
clinic during the entire study period; 5) having no plan to
travel for a long time during the study period. Specific
exclusion criteria included children with a history of
allergy to sulpha drugs or SP.
Follow-up
Subjects from both groups were actively and passively fol-
lowed during the study periods. The active follow-up was
done weekly and consisted of: 1) questioning the subjects
or parent for presence within the two past days of symp-
toms consistent with malaria including fever, headaches,
body aches, malaise, diarrhoea, vomiting, and abdominal
pain; 2) recording the axillary temperature; 3) examining
conjunctivae and palms for pallor indicating a profound
anaemia. The passive follow-up was done through contin-
uous availability of study clinicians to evaluate any medi-
cal complaint at anytime during the entire study period.Malaria Journal 2008, 7:123 http://www.malariajournal.com/content/7/1/123
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Any subject, who complains of symptom consistent with
malaria, with an axillary temperature greater or equal to
37.5°C, or with profound anaemia or jaundice, was given
a complete medical exam and laboratory assessment
including malaria smear and haemoglobin or hematocrit
measurement. The criteria for discontinuing further fol-
low-up for a volunteer were: 1) consent withdrawal, 2)
volunteer missed three consecutives follow-up visits, 3)
assessment of the study physician as to whether being in
the study was in the best interest of the volunteer.
Treatment
Subjects who were diagnosed with uncomplicated malaria
were treated immediately with standard doses of SP, and
those who were diagnosed with severe malaria were
treated with quinine according to the guidelines of
National Malaria Control Programme. They remained in
the study so that multiple episodes of malaria disease
could be detected over the course of the study period. In
vivo response to SP was assessed using the WHO 2003 pro-
tocol [11] on uncomplicated malaria cases. Clinical
assessments were made on days 1, 2, 3, 7, 14, 21 and 28
following treatment with SP, and blood smears were
obtained (by finger prick) on days 3, 7, 14, 21 and 28 to
determine the in vivo SP treatment failure. At the end of
every clinic visit, subjects and their parent/legal guardian
were encouraged to return immediately to the study clinic
and/or their primary health care system should any other
new symptoms appear.
Standard recommended treatment doses of SP (Fansidar®,
F. Hoffman-La Roche Ltd, Basel, Switzerland) was given
for IPT and for treatment of episodes of uncomplicated
malaria (1/4 tablet per 5 kg wt for age ≤12 years). All sub-
jects were observed for at least 60 minutes for vomiting. If
vomiting occurred within 30 minutes, the full dose was
repeated and if it occurred within 60 minutes, 1/2 of the
dose was repeated. Cases of SP failure, and cases of
malaria disease occurring within two weeks of a periodic
treatment in the IPT group, were treated with chloroquine
at 25 mg/kg in three days. Severe and complicated malaria
cases were treated with quinine 8 mg/kg three times a day
for five days. Serious adverse events were monitored dur-
ing the duration of the study.
Laboratory methods
Haematocrit was determined using microhaematocrit
reading device after centrifugation (IECMicro-MB centri-
fuge) and haemoglobin concentration was determined
using a portable analyzer (Hemocue, Lake Forest, CA).
Parasitaemia was assessed by counting the number of
asexual P. falciparum parasites on Giemsa-stained thick
blood films until 300 leukocytes were observed by micro-
scopists unaware of the treatment group of the subject.
Parasite densities were converted assuming 7,500 leuko-
cytes/μl. Routine quality control was performed on 10%
of the slides, with a second microscopist re-examining the
blood films while blinded to the previously recorded
result. Differences in parasitaemia of more than 10% were
resolved by an expert microscopist.
Study endpoints
The primary end point of the study was the incidence rate
of clinical malaria, defined as uncomplicated or severe
malaria for the assessment of protective efficacy and the
rebound effect. Uncomplicated malaria was defined as
signs or symptoms consistent with malaria either leading
to treatment-seeking behaviour or reported during weekly
follow-up visits accompanied by any level of parasitae-
mia. These signs and symptoms included fever at the time
of evaluation (axillary temperature ≥37.5°C by digital
thermometer), profound anaemia (conjunctival or pal-
mar pallor), jaundice, report of fever within the last two
days, lassitude, headache, body aches, diarrhoea, or
abdominal pain. Severe malaria was defined according to
the most recent WHO protocols: severe anaemia (defined
as haemoglobin <5 g/dL); parasitemia >10% or 500,000/
mm3, prostration, respiratory distress, bleeding, recent
repeated seizures, coma or obtundation, inability to
drink, or persistent vomiting. The secondary endpoint was
the non PCR corrected adequate clinical and parasitologi-
cal response (ACPR) for the in vivo response of P. falci-
parum  to SP. ACPR of P. falciparum to SP was defined
according the WHO 2003 protocol [11] a protocol already
available in 2002.
Sample size
The sample size was computed using the primary end
point which was the incidence rate of malaria disease.
Using normal approximation of square root transforma-
tion of Poisson formula, 96 persons-years of follow-up in
each group were needed in order to detect a reduction of
40% in the incidence malaria disease, with 90% power
and 95% confidence level, based on the estimated inci-
dence of 1.2 episodes per person-year in the non-treat-
ment group. To account for loss to follow up a total of 262
subjects (131 for each group) were enrolled. Using equiv-
alency study of interventions method a total of 120 in vivo
tests per arm will give more than 80% power for a maxi-
mum difference of 7% in ACPR between the two arms
assuming ACPR of 95%.
Statistical analysis
Intention to treat analysis was used. The person-time
method was used to calculate the incidence rate of malaria
disease and to account for variable length of follow-up.
The incidence rates were calculated as number of malaria
episodes divided by the number of person days of follow-
up at risk in each group. The incidence rates in the two
groups were compared adjusted for age as continuous var-Malaria Journal 2008, 7:123 http://www.malariajournal.com/content/7/1/123
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iable, using Poisson regression models in overall and for
each age category (<5 years and > = 5 years). Subjects were
not considered at risk for 28 days after a treatment for
malaria disease. Protective efficacy of two intermittent
treatments with SP was computed as 1 minus the inci-
dence rate ratio of malaria disease over the first 52 weeks.
This was also computed for the first 16 weeks to allow
comparison with other studies. Proportions of subjects
with ACPR using WHO latest protocol [11] in the two
groups were compared during the first year and the subse-
quent transmission season (53rd to 75th week in December
2003) using Pearson chi square or Fisher exact tests as
appropriate. Parasite densities were log transformed and
geometric means parasite densities were compared using
Student t test. Data were entered and verified using MS
Access and then exported to Stata (StataCorp, College Sta-
tion, Texas, US) for analysis.
Ethical considerations
The protocol was approved by the Ethical Committee of
Faculty of Medicine, Pharmacy and Dentistry of the Uni-
versity of Bamako, Mali. Community permission and
written individual consent from parent or legal guardian
were obtained before inclusion in the study.
Role of the funding source
The study was funded by the UNDP/World Bank/WHO
Special Programme for Research and Training in Tropical
Diseases (TDR), re-entry grant ID AI0828. Additional
funds came from the President Clinton donation to MRTC
through NIAID/NIH. The two institutions had no role in
the design conduct analysis and reporting of the study.
The corresponding author had full access to all the data
and had final responsibility for the decision to submit for
publication.
Results
Characteristics of the study participants
A total of 262 subjects were enrolled in this study (131 in
each arm). Baseline characteristics are summarized in
Table 1. There was no significant difference between the
two groups at baseline in term of age, gender and malaria
parasite prevalence.
Loss to follow-up
Of the 262 subjects enrolled, 30 subjects (11.4%) did not
complete one year follow up and were equally distributed
between the two groups (15 in each group). An additional
12 subjects (4.6%) did not complete the extended follow-
up 7 in treatment group and 5 in the control group (Figure
1). Overall proportion of subjects who did not complete
the follow up was similar between the two groups (16.8%
versus 15.3%, p = 0.73). The reasons for loss to follow-up
during the study were: migration to another location (n =
32), missing more three consecutive weekly visits (n = 6),
consent withdrawal (n = 3) and death from severe malaria
(n = 1).
Incidence rate of malaria disease and efficacy of sIPT after 
52 weeks of follow up
The incidence rate and protective efficacy after 52 weeks of
follow up are presented in Table 2. Overall 352 episodes
of malaria disease occurred, 221 in the control group and
130 in the sIPTc group. The incidence rates per 1000 per-
son-days at risk for the malaria disease were 5.8 and 3.2 in
the control and treatment groups respectively, giving a
protective efficacy of 44.8% (95% CI 31.5% to 55.6%).
After adjustment for age, the protective efficacy was 42.5%
(95% CI 28.6 to 53.8%.) (Table 2). When the analysis was
stratified by age categories, the incidence rate of malaria
disease was 7.3 and 3.9 episodes per 1000 person-days in
control and treatment groups respectively with an age-
adjusted PE of 46.6% (95% CI 28.0% to 60.4%) in chil-
dren less than five years of age. In children five years and
above, the incidence rate of malaria disease were 4.5 and
2.7 episodes per 1000 person-days respectively in the con-
trol and treatment group. Age adjusted PE in this age
group was 35.9% (95% CI 11.8% to 53.4%).
Five cases of severe malaria (two cases of cerebral malaria,
two cases of hyperparasitaemia, and one case of severe
anaemia) occurred during the first 12 months of the fol-
low-up, all in the control group giving an incidence rate of
0.048 episodes per 1000 persons-days at risk and a cumu-
lative incidence of 3.9% in this group.
Incidence rate of malaria disease and efficacy of sIPT after 
16 weeks of follow-up
The incidence rate and protective efficacy after the first 16
weeks of follow-up are presented in Table 3. A total of 200
malaria disease episodes occurred during the first 16
weeks of follow-up, 145 in the control group and 55 in
the group who received sIPT. The age adjusted PE in this
period was 67.5% (95% CI 55.3% to76.6%) and was not
significantly different in subjects of less than five years
compared to those aged of five years and above.
Table 1: Baseline characteristics of the study participants
sIPT + 
(n = 131)
sIPT- 
(n = 131)
p
Mean age in years (SD) 5.6 (2.9) 5.1 (2.8) n.s.
Sex (% of male) 50.4 58.0 n.s.
Parasite prevalence (%) 33.6 37.4 n.s.
Lost to follow up first year (%)
Week 1 to 52 11.4 11.4 n.s.
Week 53 to 75 5.3 3.8 n.s.
SD = standard deviation
sIPT - = control group
sIPT + = treatment group
n.s. not significantMalaria Journal 2008, 7:123 http://www.malariajournal.com/content/7/1/123
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Flow Chart Figure 1
Flow Chart.
262 children enrolled 
131 children randomized to 
sIPT-  arm 
131 children randomized to 
sIPT+  arm 
15 eliminated from study by week 52 
(14 left study area, 1 missed consecutive 
visits)
15 eliminated from study by week 52 
(12 left study area, 2 missed consecutive 
visits, one died) 
116 completed 52 weeks of 
follow up   
116 completed 52 weeks of 
follow up   
111 completed 75 weeks of 
follow-up
109 completed 75 weeks of 
follow-up
7 eliminated from study by 
week 75                          
(3 left study area, 2 missed 
consecutive visits, 2 consent 
withdrawal)
5 eliminated from study by week 75         
(3 left study area, 1 missed 
consecutive visits, 1 consent 
withdrawal)
Table 2: Incidence rate of clinical malaria and protective efficacy after 52 weeks of follow-up per treatment group and age category
<5 years 5–10 years All
sIPT- sIPT + sIPT- sIPT + sIPT- sIPT +
Number of malaria episodes 127 65 94 65 221 130
Person-days (-years) of follow 
up
17311 (47.6) 16590(45.6) 20799 (57.1) 24025 (66.0) 38110 (104.7) 40615 (111.6)
Incidence rate malaria disease 
per 1000 person-days (-years) 
of follow up
7.3 (2.67) 3.9(1.43) 4.5 (1.65) 2.7 (0.98) 5.8 (2.11) 3.2 (1.16)
Unadjusted PE in % (95% CI) Reference group 46.6 (28.0–60.4 Reference group 40.1 (17.9–56.4) Reference group 44.8 (31.5–55.6)
Age adjusted PE in % (95% CI) Reference group 46.6 (28.0 – 60.4) Reference group 35.9 (11.8–53.4) Reference group 42.5 (28.6 – 53.8)
sIPT - = control group
sIPT + = treatment group
PE = Protective efficacyMalaria Journal 2008, 7:123 http://www.malariajournal.com/content/7/1/123
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Incidence rate of malaria disease after cessation of sIPT 
during the next subsequent transmission season (weeks 53 
to 75)
During the subsequent malaria transmission season in
2003, a total of 503 malaria episodes occurred, with 255
cases in the treatment group and 248 in the control group.
The incidence rates of malaria disease were similar
between the two groups 23.0 episodes per 1,000 persons-
days in the treatment group and 21.5 episodes per 1,000
persons-days in the control group with age adjusted Inci-
dence Rate Ration (IRR) = 1.07 (95% CI 0.90 to 1.27, p =
0.46). During this extended follow up period two cases of
severe malaria occurred, both type cerebral malaria and in
the control group.
In vivo response of P. falciparum to SP
Of the 351 malaria episodes during the first year, valid in
vivo tests were performed in 331 (94.3%) with 119/130
(91.5%) in the control group and 212/221 (95.9%) in the
sIPT group. Table 4 shows that non PCR corrected 28 days
Adequate Clinical and Parasitological Response (ACPR)
was similar in the two groups in overall (92.9% in the
control group vs. 94.1% in the sIPT group) and when the
analysis was stratified by age categories. Mean parasitae-
mia at day 0 was also similar between the two groups with
geometric means parasitaemia per μl of 11,480 (95% CI
8,770 to 15,027) in the control group versus 9,478 (95%
CI 6,639 to 13,530) in the treatment group, p = 0.39.
During the extended surveillance following cessation of
sIPT (53rd to 75th week), valid in vivo tests were performed
in 472 (93.8%) of the 503 malaria episodes were treated
with SP. Mean parasitaemia at day 0 was also similar
between the two groups with geometric means parasitae-
mia per μl of 8,191 (95% CI of 6,367 to 10,538) in the
control group versus 9,903 (95% CI 7,704 to 12,730) in
the treatment group, p = 0.29.
In vivo responses per treatment and follow up period are
presented in Table 5. The ACPR were similar between the
two groups (87.9% versus 89.6%). The same similarities
were found when the analysis was done in children less
than five years of age or in those aged of five years and
above.
Table 3: Incidence rate of malaria disease and protective efficacy after 16 weeks of follow up per treatment group and age category
<5 years 5–10 years All
sIPT- sIPT + sIPT- sIPT + sIPT- sIPT +
Number of malaria episodes 86 30 59 25 145 55
Person-days of follow up 4797 5474 6207 7875 11004 13349
Incidence rate malaria disease 
per 1000 person-days of follow 
up
17.9 5.5 9.5 3.2 13.2 4.1
PE in % (95% CI) Reference group 68.7 (57.4–77.1) Reference group 66.6 (46.7–79.1) Reference group 68.7 (57.4 – 76.1)
Age adjusted PE in % (95% CI) Reference group 69.4 (53.6–79.8) Reference group 63.4 (41.5–77.1) Reference group 67.5 (55.3–76.6)
sIPT - = control group
sIPT + = treatment group
PE = Protective efficacy
Table 4: In vivo response of P. falciparum to SP during the first year of follow up group age categories and treatment groups
< 5 years 5–10 years All
Outcome sIPT-
(n = 122)
sIPT + 
(n = 58)
sIPT- 
(n = 90)
sIPT + 
(n = 61)
sIPT- 
(n = 212)
sIPT + 
(n = 119)
ACPR 93.4 93.1 92.2 95.1 92.9 94.1
ETF 0.0 1.7 0.0 0 0.0 0.8
LCF 0.0 0.0 0.0 0 0.0 0.0
LPF 6.6 5.2 7.8 4.9 7.1 5.0
sIPT - = control group
sIPT + = treatment group
ACPR = adequate clinical and parasitological response
ETF = early treatment failure
LPF = late parasitological failureMalaria Journal 2008, 7:123 http://www.malariajournal.com/content/7/1/123
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Overall there was a reduction in the efficacy of SP during
the extended follow-up compared to the first year of the
follow up, especially in children less than five years of age.
Safety
No SP related serious adverse event was recorded during
the study period. No subject was withdrawn because of
allergy to SP.
Discussion
This study assessed the impact of two doses of intermit-
tent preventive treatment with SP at 8-week intervals in
children of six months to 10 years of age targeting the
transmission season in Kambila, Mali and found a reduc-
tion of 42.5% in annual incidence of clinical malaria.
When SP plus single dose of artesunate was given at
monthly intervals in an area with seasonal malaria trans-
mission, Cisse et al [12] in Senegal found a reduction of
86% in incidence of clinical malaria children less than five
years of age over 13 weeks period. This higher efficacy can
be explained by the shorter time interval between treat-
ments (four weeks instead of eight weeks), the number of
intermittent treatments (three instead of two) and the
shorter duration of the follow up (13 instead 52 weeks)
[12]. Furthermore when the analysis of the efficacy of the
two doses of intermittent preventive treatment with SP at
8-week intervals was limited to the first 16 weeks of follow
up, the protective efficacy was 69.4% in children aged less
than five years. Although the incidence rate of clinical
malaria was higher in children less than five years of age
compared to those of five years and above, the differences
in efficacy of the strategy were not significantly different
suggesting that IPT is also appropriate for older children.
While several studies have assessed the impact of IPT in
pregnant women and infants, few studies have assessed
the impact of this strategy in children. Several studies have
shown that intermittent treatment given at 3, 6, 9 months
of age reduced the incidence of clinical episodes by 20 to
60% with strong variations according to transmission
duration and the seasonality [7,8,13,14]. In areas of sea-
sonal malaria transmission, the burden of malaria
remains high in older children in addition to infants [15-
20]. Furthermore, more than 80% of the malaria cases in
non-irrigated areas occurred during the 4–6 months of the
transmission season [21], suggesting that sIPT is an appro-
priate preventive strategy for malaria control.
Unlike the use of other malaria control strategies such as
use of insecticide-impregnated material that require daily
implementation, this strategy requires only a twice-yearly
treatment while offering significant protection against
malaria. This simple strategy can be delivered through
schools and/or local and national campaigns. Despite the
current evidence and recommendation for use of insecti-
cide-treated nets (ITN), this strategy remains largely
under-utilized in Mali and many parts of Africa [22-24].
Increasingly, as efforts are being made to expand coverage
of ITN it will be interesting to assess the efficacy of sIPT in
children in the context of wide use of ITN.
The incidence rates of malaria disease (including severe
malaria) reported in this randomized control trial were
similar to those reported in previous studies in Mali
[18,25]. This suggests an unbiased measure of the out-
come despite the fact that the study was not a placebo con-
trolled one, and that similar efficacy can be achieved by
sIPTc in these areas.
There was no significant difference in SP efficacy in vivo
between the treatment and control groups during the two
periods of follow up using the WHO 2003 protocol for
assessing the in vivo efficacy of antimalarials [11]. How-
ever there was a reduction in SP efficacy during the
extended follow up period compared to the first year of
follow up, especially among children less than five years
of age. It is difficult to conclude if this reduction in SP in
vivo efficacy was due to the sIPTc or was rather the
Table 5: In vivo response of P. falciparum to SP during the extended period of follow up after cessation of sIPT implementation per age 
categories and treatment group
1–4 years 5–11 years All
Outcome sIPT- 
(n = 102)
sIPT + 
(n = 104)
sIPT- 
(n = 130)
sIPT + 
(n = 136)
sIPT- 
(n = 232)
sIPT + 
(n = 240)
ACPR 87.3 84.6 88.5 93.4 87.9 89.6
ETF 0.0 1.0 1.5 0.7 0.9 0.8
LCF 1.0 0.0 0.0 0.0 0.4 0.0
LPF 11.8 14.4 10.0 5.9 10.8 9.6
sIPT - = control group
sIPT + = treatment group
ACPR = adequate clinical and parasitological response
ETF = early treatment failure
LPF = late parasitological failureMalaria Journal 2008, 7:123 http://www.malariajournal.com/content/7/1/123
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expected decrease in efficacy due to the use of SP for treat-
ment of malaria episodes in this population. In this study,
uncomplicated malaria cases in both arms were treated
with SP (2nd line malaria treatment in Mali at the time of
the study). While the higher efficacy and the longer pro-
phylactic effect of SP compared to choloroquine (the first
line treatment at the time of the study), provide more ben-
efice for the study participants, this may contribute to the
lack of difference in in vivo response between the two arms
and the trend towards a lower efficacy during the extended
follow up period.
Cisse  et al [12] have found variation in frequency of
molecular markers to SP resistance according to the sea-
son, without clear link with the intermittent preventive
treatment. Results of studies undertaken by the IPTi con-
sortium will bring more insight on the impact of IPT on
drug resistance and whether this is an acceptable price to
pay for the substantive benefit of this strategy and whether
the combination with artesunate would be able to reduce
the risk of increased resistance.
As shown in other studies [7,8,12] the cessation of the
strategy was not associated with an increase of malaria dis-
ease during the subsequent transmission season. However
in all these studies, IPT was given for a short time usually
one year. It would be interesting to assess whether sea-
sonal IPT in children given over longer periods impairs
immunity to malaria.
In conclusion two malaria intermittent treatments target-
ing the peak of the transmission season have substantially
reduced the incidence of clinical malaria in this area with
intense seasonal transmission without a rebound effect
after cessation. The strategy is simple and is likely to be
very effective in reducing malaria burden in areas with
seasonal malaria transmission.
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